Univerzita Pardubice Fakulta chemicko- technologická

Univerzita Pardubice

Zaměstnanci
|
Studenti
English

Publikace detail

Concentration Changes of Sulfatides and Sphingomyelins in Body Fluids Reflect Cancer Progression of Renal Cell Carcinoma Patients

Autoři: Jirásko Robert | Idkowiak Jakub | Wolrab Denise | Kvasnička Aleš | Friedecký David | Polanski Krzysztof | Študentová Hana | Študent Vladimír | Melichar Bohuslav | Holčapek Michal

Rok: 2022

Druh publikace: ostatní - přednáška nebo poster

Strana od-do: nestránkováno

Tituly:

Jazyk	Název	Abstrakt	Klíčová slova
eng	Concentration Changes of Sulfatides and Sphingomyelins in Body Fluids Reflect Cancer Progression of Renal Cell Carcinoma Patients	Renal cell carcinoma (RCC) represents the most common type of kidney cancer and is associated with high mortality despite the progress of surgical and medical management. A non-invasive diagnostic test is still not available due to the lack of RCC-specific biomarkers in body fluids. We have previously described a significantly altered profile of sulfatides in RCC tumor tissues, motivating us to investigate whether these alterations are reflected in collectible body fluids and whether they can enable RCC detection. We collected and further analyzed 143 plasma, 100 urine, and 154 tissue samples from 155 kidney cancer patients, together with 207 plasma and 70 urine samples from 214 healthy controls. Mass spectra were measured using a high-resolution MALDI LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) and 9 aminoacridine was used as MALDI matrix. For the first time, we report the significant concentration changes of sulfatides in plasma and urine of RCC patients. Elevated concentrations of lactosylsulfatides, decreased concentrations of sphingomyelins with long saturated N-fatty acyls, and hydroxylated sulfatides are the crucial alterations in RCC and are more emphasized in the advanced tumor stage. Similar trends in body fluids and tissues indicate that RCC-related processes widely influence lipid metabolism. We built binary classifiers that detect RCC based on plasma and urine lipidome dysregulations, and we show that the plasma lipidome alterations enable distinguishing between early-stage RCC and controls. Our results demonstrate the considerable potential of specific lipid screening in biofluids for RCC detection and monitoring in clinical settings.	cancer biomarkers; sulfatide; sphingomyelins; lipidomics; renal cell carcinoma